Trial Profile
A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 05 Jan 2022 Status changed from active, no longer recruiting to completed.
- 19 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 17 Sep 2020 Results published in the Clinical Cancer Research